Oncology Central

Pancreatic cancer screening using a multiplatform human serum metabolomics system


Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death. PDAC is the fourth and fifth leading cause of cancer death in males and females in developed countries, respectively. Worldwide, there were 277,668 new cases and 266,029 deaths from PDAC in 2008 [1]. PDAC has a poor prognosis (5-year survival rate: 5–6%) [2,3] due to the difficulty of diagnosing the disease early [4]. Only surgical resection can cure PDAC, but more than 80% of patients with PDAC have unresectable tumors because its disease is commonly discovered at a late stage [5,6].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.